Assessing Safety of Cervical Spine Fusion With NMP®
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorRed Rock Regeneration Inc.
About this trial
The goal of this retrospective chart review study is to assess safety of NMP® in the treatment of cervical spine degenerative conditions by assessing the incidence and nature of AEs in follow-up (minimum of 90 days and up to 2 year post-operatively) as well as reoperation rates.
Eligibility criteria
Qualifiers
Patients treated with NMP® for Cervical (C2-T1) Interbody fusion (2022-2025) at the study site.
Minimum of 90-day post-operative follow up data available
Disqualifiers
Patients with no follow-up data within 3 months from the surgery date due to missed postoperative appointments.
Trial design
Treatments tested in this trial
- Natural Matrix Protein (NMP) Fibers
- Cervical interbody fusion
Treatment groups
300 Participants
are divided into 1 treatment groupLocations
1Alabama Back Institute35501, JasperAlabama, United States
Sponsors and collaborators
Red Rock Regeneration Inc.
Lead sponsor
Source ClinicalTrials.gov